Darling Ingredients Inc. has announced the publication of preclinical and clinical studies in the Wiley Journal of Food Science and Nutrition, highlighting the impact of a specific collagen peptide composition on post-meal blood glucose spikes. The research focuses on Nextida GC, a product developed by Rousselot, Darling Ingredients' collagen and gelatin brand.
Nextida GC and Blood Glucose Regulation
The Nextida library features a collection of specific collagen peptide compositions designed for targeted health benefits. Nextida GC, the first product in this range, has demonstrated significant potential in mitigating post-meal glucose spikes in healthy individuals, including those with normoglycemia and prediabetes.
Clinical Trial Results
In a proof-of-concept clinical trial, participants who consumed 5- or 10-gram doses of Nextida GC 30 minutes before a meal experienced an average reduction of 42% in blood glucose spike after the meal. These results suggest a promising avenue for managing blood sugar levels through natural supplementation.
Supporting Statements
"We are proud of this publication, which supports our discoveries, underscores the robustness of our scientific research, and highlights the potential of Nextida GC," said Randall C. Stuewe, Chairman and CEO, Darling Ingredients. "This product represents a significant breakthrough in the field of collagen peptides and offers a promising new option for individuals seeking safe and natural supplements to enhance their well-being."
Darling Ingredients' Commitment
Darling Ingredients is dedicated to leading the development of new collagen-based products that offer health benefits beyond traditional applications, meeting the growing consumer demand for natural and effective health solutions. The company operates over 260 facilities in more than 15 countries, processing approximately 15% of the world's animal agricultural by-products and producing about 30% of the world's collagen.
